Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FDA Approves Inavolisib for PIK3CA-Mutated HR+/HER2− MBC
The US Food and Drug Administration (FDA) has approved inavolisib (Itovebi, Genentech) in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−), locally advanced or metastatic breast cancer following recurrence on…
English